Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Nicola Ferri, Alberto Corsini, Cesare Sirtori & Massimiliano Ruscica. (2017) PPAR-α agonists are still on the rise: an update on clinical and experimental findings. Expert Opinion on Investigational Drugs 26:5, pages 593-602.
Read now
Read now
Articles from other publishers (30)
Mona Mohamed Ibrahim Abdalla. (2023) Serum resistin and the risk for hepatocellular carcinoma in diabetic patients. World Journal of Gastroenterology 29:27, pages 4271-4288.
Crossref
Crossref
Andrea Boccatonda, Lorenzo Andreetto, Damiano D’Ardes, Giulio Cocco, Ilaria Rossi, Susanna Vicari, Cosima Schiavone, Francesco Cipollone & Maria Teresa Guagnano. (2023) From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications. Biomedicines 11:3, pages 883.
Crossref
Crossref
Tianyu Mao, Rui Yang, Yi Luo & Kang He. (2022) Crucial role of T cells in NAFLD-related disease: A review and prospect. Frontiers in Endocrinology 13.
Crossref
Crossref
Francesco Baratta, Laura D'Erasmo, Simone Bini, Daniele Pastori, Francesco Angelico, Maria Del Ben, Marcello Arca & Alessia Di Costanzo. (2022) Heterogeneity of non-alcoholic fatty liver disease (NAFLD): Implication for cardiovascular risk stratification. Atherosclerosis 357, pages 51-59.
Crossref
Crossref
Usman Sabir, Hafiz Muhammad Irfan, Alamgeer, Ihtisham Umer, Zahid Rasul Niazi & Hafiz Muhammad Mazhar Asjad. (2022) Phytochemicals targeting NAFLD through modulating the dual function of forkhead box O1 (FOXO1) transcription factor signaling pathways. Naunyn-Schmiedeberg's Archives of Pharmacology 395:7, pages 741-755.
Crossref
Crossref
Bin Liu, Huan Zheng, Guanghui Liu & Zhiling Li. (2022) Adiponectin is Inversely Associated with Insulin Resistance in Adolescents
with Nonalcoholic Fatty Liver Disease. Endocrine, Metabolic & Immune Disorders - Drug Targets 22:6, pages 631-639.
Crossref
Crossref
Hao Xu & Lin Wang. (2021) The Role of Notch Signaling Pathway in Non-Alcoholic Fatty Liver Disease. Frontiers in Molecular Biosciences 8.
Crossref
Crossref
Libor Vítek. (2021) The Protective Role of the Heme Catabolic Pathway in Hepatic Disorders. Antioxidants & Redox Signaling 35:9, pages 734-752.
Crossref
Crossref
Paola Dongiovanni, Erika Paolini, Alberto Corsini, Cesare R. Sirtori & Massimiliano Ruscica. (2021) Nonalcoholic fatty liver disease or metabolic dysfunction‐associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches. European Journal of Clinical Investigation 51:7.
Crossref
Crossref
Mi Na Kim, Kyungdo Han, Juhwan Yoo, Yeonjung Ha, Young Eun Chon, Ju Ho Lee, Tracey G. Simon, Andrew T. Chan & Seong Gyu Hwang. (2021) Body weight variability and the risk of cardiovascular outcomes in patients with nonalcoholic fatty liver disease. Scientific Reports 11:1.
Crossref
Crossref
Xuefen Chen, Yong Gao, Xiaobo Yang, Haiying Zhang, Zengnan Mo & Aihua Tan. (2020) Relationship of FTO gene variations with NAFLD risk in Chinese men. Open Life Sciences 15:1, pages 860-867.
Crossref
Crossref
Letícia S. Figueiredo, Kênia M. Oliveira, Israelle N. Freitas, Joel A. SilvaJrJr, Juliana N. Silva, Bianca C. Favero-Santos, Maria Lúcia Bonfleur, Everardo M. Carneiro & Rosane A. Ribeiro. (2020) Bisphenol-A exposure worsens hepatic steatosis in ovariectomized mice fed on a high-fat diet: Role of endoplasmic reticulum stress and fibrogenic pathways. Life Sciences 256, pages 118012.
Crossref
Crossref
Ayokanmi Ore, Regina Ngozi Ugbaja, Abideen Idowu AdeogunOluseyi Adeboye Akinloye. (2020) An albino mouse model of nonalcoholic fatty liver disease induced using high-fat liquid “Lieber-DeCarli” diet: a preliminary investigation. Porto Biomedical Journal 5:4, pages e071.
Crossref
Crossref
Marica Meroni, Miriam Longo, Anna L. Fracanzani & Paola Dongiovanni. (2020) MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD. EBioMedicine 57, pages 102866.
Crossref
Crossref
Hideki Fujii & Norifumi Kawada. (2020) The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease. International Journal of Molecular Sciences 21:11, pages 3863.
Crossref
Crossref
Ying Bai, Xueli Bao, Guangjian Jiang, Dongyu Ge, Weipeng He, Dandan Zhao, Yi Zhang, Ruijuan Dong, Jing Hua, Nan Yang, Fangfang Mo & Sihua Gao. (2020) Jiang Tang Xiao Ke Granule Protects Hepatic Tissue of Diabetic Mice Through Modulation of Insulin and Ras Signaling – A Bioinformatics Analysis of MicroRNAs and mRNAs Network. Frontiers in Pharmacology 11.
Crossref
Crossref
Nahum Méndez-Sánchez, Eira Cerda-Reyes, Fátima Higuera-de-la-Tijera, Ana K. Salas-García, Samantha Cabrera-Palma, Guillermo Cabrera-Álvarez, Carlos Cortez-Hernández, Luis A Pérez-Arredondo, Emma Purón-González, Edgar Coronado-Alejandro, Arturo Panduro, Heriberto Rodríguez-Hernández, Vania C. Cruz-Ramón, Alejandro Valencia-Rodríguez, Xingshun Qi, Nashla Hamdan-Pérez, Nancy E. Aguilar-Olivos, Beatriz Barranco-Fragoso, Oscar Ramírez-Pérez & Alfonso Vera-Barajas. (2020) Dyslipidemia as a risk factor for liver fibrosis progression in a multicentric population with non-alcoholic steatohepatitis. F1000Research 9, pages 56.
Crossref
Crossref
Su-Tong Liu, Kai-Qi Su, Li-Hui Zhang, Ming-Hao Liu & Wen-Xia Zhao. (2020) Hypoglycemic agents for non-alcoholic fatty liver disease with type 2 diabetes mellitus. Medicine 99:32, pages e21568.
Crossref
Crossref
Marica Meroni, Miriam Longo, Veronica Erconi, Luca Valenti, Stefano Gatti, Anna Ludovica Fracanzani & Paola Dongiovanni. (2019) mir-101-3p Downregulation Promotes Fibrogenesis by Facilitating Hepatic Stellate Cell Transdifferentiation During Insulin Resistance. Nutrients 11:11, pages 2597.
Crossref
Crossref
D. Dondossola, C. Lonati, A. Zanella, M. Maggioni, B. Antonelli, P. Reggiani, S. Gatti & G. Rossi. (2019) Preliminary Experience With Hypothermic Oxygenated Machine Perfusion in an Italian Liver Transplant Center. Transplantation Proceedings 51:1, pages 111-116.
Crossref
Crossref
Hessah Al‑Muzafar & Kamal Amin. (2018) Thiazolidinedione induces a therapeutic effect on hepatosteatosis by regulating stearoyl‑CoA desaturase‑1, lipase activity, leptin and resistin. Experimental and Therapeutic Medicine.
Crossref
Crossref
Susanne Schuster, Daniel Cabrera, Marco Arrese & Ariel E. Feldstein. (2018) Triggering and resolution of inflammation in NASH. Nature Reviews Gastroenterology & Hepatology 15:6, pages 349-364.
Crossref
Crossref
Fengling Wang, Yifan Wu, Xiaoting Xie, Jing Sun & Weidong Chen. (2018) Essential role of nuclear receptors for the evaluation of the benefits of bioactive herbal extracts on liver function. Biomedicine & Pharmacotherapy 99, pages 798-809.
Crossref
Crossref
Martine C. Morrison, Robert Kleemann, Arianne van Koppen, Roeland Hanemaaijer & Lars Verschuren. (2018) Key Inflammatory Processes in Human NASH Are Reflected in Ldlr−/−.Leiden Mice: A Translational Gene Profiling Study. Frontiers in Physiology 9.
Crossref
Crossref
Kumiko Shiba, Kyoichiro Tsuchiya, Chikara Komiya, Yasutaka Miyachi, Kentaro Mori, Noriko Shimazu, Shinobu Yamaguchi, Naomi Ogasawara, Makoto Katoh, Michiko Itoh, Takayoshi Suganami & Yoshihiro Ogawa. (2018) Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH. Scientific Reports 8:1.
Crossref
Crossref
Arianne van Koppen, Lars Verschuren, Anita M. van den Hoek, Joanne Verheij, Martine C. Morrison, Kelvin Li, Hiroshi Nagabukuro, Adalberto Costessi, Martien P.M. Caspers, Tim J. van den Broek, John Sagartz, Cornelis Kluft, Carine Beysen, Claire Emson, Alain J. van Gool, Roel Goldschmeding, Reinout Stoop, Ivana Bobeldijk-Pastorova, Scott M. Turner, Guido Hanauer & Roeland Hanemaaijer. (2018) Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model. Cellular and Molecular Gastroenterology and Hepatology 5:1, pages 83-98.e10.
Crossref
Crossref
Paola Dongiovanni & Luca Valenti. (2017) A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences 18:7, pages 1534.
Crossref
Crossref
Paola Dongiovanni, Marica Meroni, Guido Alessandro Baselli, Giulia Alessandra Bassani, Raffaela Rametta, Alessandro Pietrelli, Marco Maggioni, Federica Facciotti, Valentina Trunzo, Sara Badiali, Silvia Fargion, Stefano Gatti & Luca Valenti. (2017) Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease. Clinical Science 131:12, pages 1301-1315.
Crossref
Crossref
Rong Zhang, Keran Cheng, Shizan Xu, Sainan Li, Yuqing Zhou, Shunfeng Zhou, Rui Kong, Linqiang Li, Jingjing Li, Jiao Feng, Liwei Wu, Tong Liu, Yujing Xia, Jie Lu, Chuanyong Guo & Yingqun Zhou. (2017) Metformin and Diammonium Glycyrrhizinate Enteric-Coated Capsule versus Metformin Alone versus Diammonium Glycyrrhizinate Enteric-Coated Capsule Alone in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Gastroenterology Research and Practice 2017, pages 1-11.
Crossref
Crossref
Daniel Cabrera, Alex Ruiz, Claudio Cabello-Verrugio, Enrique Brandan, Lisbell Estrada, Margarita Pizarro, Nancy Solis, Javiera Torres, Francisco Barrera & Marco Arrese. (2016) Diet-Induced Nonalcoholic Fatty Liver Disease Is Associated with Sarcopenia and Decreased Serum Insulin-Like Growth Factor-1. Digestive Diseases and Sciences 61:11, pages 3190-3198.
Crossref
Crossref